A registration-enabling study of the combination of TRC105 and Nexavar in Hepatocellular Carcinoma (HCC)

Trial Profile

A registration-enabling study of the combination of TRC105 and Nexavar in Hepatocellular Carcinoma (HCC)

Planning
Phase of Trial: Phase III

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs Carotuximab (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors TRACON Pharmaceuticals
  • Most Recent Events

    • 23 Jan 2018 New trial record
    • 19 Jan 2018 According to a TRACON Pharmaceuticals media release, the company is planning to discuss this trial with regulatory authorities.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top